Cyclerion Therapeutics, Inc.
NCM: CYCNLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cyclerion Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CYCN Z-Score →About Cyclerion Therapeutics, Inc.
Healthcare
Biotechnology
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
📊 Fundamental Analysis
Cyclerion Therapeutics, Inc. demonstrates a profit margin of -170.1%, which is below the sector average, suggesting competitive pressure.
The company recently reported -43.2% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -39.3%, which indicates that capital utilization is currently under pressure.
At a current price of $2.91, CYCN currently sits at the 25th percentile of its 52-week range (Range: $1.03 - $8.48).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$12.60M
Trailing P/E
--
Forward P/E
-2.22
Beta (5Y)
0.89
52W High
$8.48
52W Low
$1.03
Avg Volume
4.80M
Day High
Day Low